19 June 2014 - Below is a list of forthcoming submissions that have recently been added to the SMC's work programme.

• Bevacizumab (Avastin)
• Bosutinib hydrochloride (Bosulif)
• Capsaicin (Qutenza)
• Ceftobiprole medocaril (Zevtera)
• Cetuximab (Erbitux)
• Colecalciferol (Invita D3)
• Dabigatran etexilate mesylate (Pradaxa)
• Misoprostol (Mysodelle)
• Obinutuzumab (Gazyvaro)

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/Forthcoming_Submissions